Table 1 Demographic characteristics of the participants.

From: Neutralization activity of sera/IgG preparations from fully BNT162b2 vaccinated individuals against SARS-CoV-2 Alpha, Beta, Gamma, Delta, and Kappa variants

 

Day-7

Day-28

Day-60

Day-90

Day-150

(1 week post 1st dose)

(1 week post 2nd dose)

Participants (all)*

225

220

211

210

208

Age

20–39 y.o.

97 (43.1%)

92

84

84

82

40–59 y.o.

110 (48.9%)

110

109

108

109

60–y.o.

18 (8.0%)

18

18

18

17

Gender

Men

68 (30.2%)

68

63

61

62

Women

157 (69.8%)

152

148

149

146

Job

Physicians

36 (16.0%)

    

Nurses

125 (55.6%)

    

Others

64 (28.4%)

    
  1. *None of the participants were in immunodeficient states or were receiving immunosuppressants or steroids. Two participants had previously experienced SARS-CoV-2 infection and were excluded from the present study since day-28. None of other participants experienced COVID-19-related symptoms and proved to be negative for antibodies against serum SARS-CoV-2 nucleocapsid throughout the study period.
Back to article page